Last reviewed · How we verify
NCT06837298
The Effect of Vicia Faba Hydrolysate Supplementation on Muscle Strength Recovery
NA trial testing Placebo control capsules in Muscle Damage in 76 participants. Currently enrolling.
30 September 2025
Quick facts
| Lead sponsor | PepsiCo Global R&D |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 76 |
| Start date | 7 February 2025 |
| Primary completion | 30 September 2025 |
| Estimated completion | 30 September 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Placebo control capsules
- PeptiStrong® supplement capsules with same appearance as placebo capsules
- PeptiStrong® supplement capsules following muscle damaging exercise on Day 14
Conditions studied
- Muscle Damage — all drugs for Muscle Damage →
- Muscle — all drugs for Muscle →
Sponsor
PepsiCo Global R&D — full company profile →
Who can join
Adults 18 to 45, any sex, with Muscle Damage or Muscle. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To investigate the effect of Vicia faba protein concentrate, a protein derived from Fava bean extract, on delayed onset muscle soreness (DOMS). Participants receive either 2.4g/day of PeptiStrong® supplement capsules or placebo capsules for 14 days until a strenuous exercise session. For the last 3 days, 2/3 of them stay on the same treatment and 1/3 of them switch from placebo to PeptiStrong®.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06837298
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Muscle Damage
Currently open trials in the same condition.
- NCT06432868 — Solarplast (R) Supplementation Effects Following High-intensity Resistance Exercise · NA · recruiting
- NCT06992271 — Comparing Two Eccentric Protocols on Muscle Damage · NA · recruiting
- NCT04900506 — Surgical Approach in Hemiarthroplasty. A Randomized Clinical Trial Comparing Posterior and Anterior Approach · NA · active not recruiting
- NCT04549610 — HMB and Exercise-induced Muscle Damage · Phase 2, PHASE3 · recruiting
- NCT03660969 — Reliability of Cardiac Troponins for the Diagnosis of Myocardial Infarction in the Presence of Skeletal Muscle Disease · active not recruiting
Other PepsiCo Global R&D trials
Trials by the same sponsor.
- NCT07429201 — Comparing an Electrolyte-Carbohydrate Beverage to Water During Ramadan · NA · completed
- NCT07400614 — Evaluating the Impact of Energy Drink Formulas on Alertness for an Extended Period · NA · recruiting
- NCT07427654 — Determination of the Glycemic Index of Products Varying in Levels of Refined and Whole Grain Corn · NA · completed
- NCT07298863 — The Effect of Hydration Status on Substrate Oxidation at Rest and During Light and Moderate Exercise · NA · recruiting
- NCT07217834 — Effects of a Glycerol-Electrolyte Beverage on Fluid Balance in Healthy Euhydrated Men and Women · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06837298 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by PepsiCo Global R&D
- Last refreshed: 20 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06837298.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing